arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Verastem, Inc.

VSTM
$8.38 ▲ +0.37 (+4.62%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
63 Visible periods
31 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Verastem, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF Margin (%). These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $839.0M
Dividend Yield
Revenue Growth 1775.4%
Op. Margin -81.6%
ROIC -67.0%
FCF / Share $-0.44
Trailing P/E
Price / Book 15.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$40.08M
↑ +1775.4%
Net Income Profit after all expenses
$-36.59M
↑ +29.8%
Operating Margin Operating profit as % of sales
-81.6%
↑ +66.1%
FCF / Share Free cash flow per share
$-0.44
↑ +17.3%
Long-Term Debt Long-term obligations
$40.72M
↑ +0.5%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -235.0% is weak on an absolute basis (target > 10%)
  • FCF Margin (%)FCF Margin (%) of -444.8% is weak on an absolute basis (target > 10%)
  • Interest CoverageInterest Coverage of -149.50x is weak on an absolute basis (target > 5x)
  • FCF / Net IncomeFCF / Net Income of 0.66x is weak on an absolute basis (target > 1x)

Health Breakdown

Profitability
18
Financial Health
18
Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 63 quarters